| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2018: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2017: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Outline of Final Research Achievements |
Previously, we revealed that intravenous injection of miR-143 suppressed lung metastasis of human osteosarcoma cells in a mouse model. In this study, we examined whether the invasion and metastasis of canine osteosarcoma cells could be suppressed by miR-143 injection which would serve as a basis for a future preclinical study using dogs. Transfection of miR-143 inhibited cell invasion and injection of miR-143 suppressed lung metastasis of canine osteosarcoma cells in a mouse model. A carrier is needed to safely and efficiently introduce miR-143 into tumor cells. Although some peptides or chitosan were used as carriers, their solubility and efficiency for transfecting miR-143 into tumor cells were not sufficient.
|
